Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propafenone + flecainide + sotalol + amiodarone
- Development stage
- Unknown
- Lead developer
- E. Meshalkin National Medical Research Centre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Propafenone + flecainide + sotalol + amiodarone refers to a therapeutic regimen of anti-arrhythmic drugs (AADs) utilized as a comparator arm in clinical research conducted by the Meshalkin Research Institute of Pathology of Circulation. This regimen includes Class IC agents (propafenone, flecainide) and Class III agents (sotalol, amiodarone), which are selected based on the presence or absence of structural heart disease in patients with paroxysmal atrial fibrillation (PAF). These small molecule drugs function by inhibiting various cardiac ion channels—specifically sodium and potassium channels—and antagonizing adrenergic receptors to stabilize the cardiac membrane and maintain sinus rhythm. The regimen was specifically evaluated in the context of managing patients who experienced recurrence of AF after an initial pulmonary vein isolation (PVI) procedure.
- Other names
- Anti-Arrhythmia AgentsAAD therapypropafenone + flecainide + sotalol + amiodarone-Meshalkin Research Institute of Pathology of Circulation
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)ADRB1 (β1)ADRA1A (α1A)ADRB2 (β2)LTCC (Voltage-gated calcium channel (L-type))KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on propafenone + flecainide + sotalol + amiodarone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propafenone + flecainide + sotalol + amiodarone.